As prostate cancer growth is dependent on androgens, androgen deprivation therapy (ADT), which includes surgical castration or medical therapy with gonadotropin-releasing hormone (GnRH) agonists or GnRH antagonists, is standard therapy for patients with metastatic prostate cancer recurrence after definitive therapy, or inoperable prostate cancer. This evidence concerns the gene GNRH1 and prostate carcinoma.